In addition to HIV treatment, CDK9 inhibitors are promising therapeutics against cancers and leukemia, with specific features that target transcriptional elongation in malignant cells and viral transcription in HIV-infected cells [[1], [2], [3], [4],38]. The gene discussed is CDK9; the disease is leukemia.